Skip to main content

Table 3 Relative risks of outcomes according to type of treatment (ACE inhibitor vs CCB and diuretics* vs ACE inhibitor) and outcome (based on meta-analyses)

From: Choice of generic antihypertensive drugs for the primary prevention of cardiovascular disease - A cost-effectiveness analysis

ACE inhibitor vs. CCB (all included)

Outcome

RCTs

Patients

RR (random), 95% CI

Mortality (total)

2

22,503

1.05 [0.98 til 1.11]

AMI

2

22,503

0.97 [0.84 til 1.13]

Stroke

2

22,503

1.13 [0.97 til 1.32]

Heart failure

2

22,503

0.85 [0.78 til 0.94]

Angina

1

18,102

1.07 [0.99 til 1.17]

Diuretics vs. ACE inhibitor (all included)

Mortality (total)

3

31,249

1.00 [0.95 til 1.07]

AMI

2

30,392

1.01 [0.88 til 1.17]

Stroke

3

31,249

0.88 [0.80 til 0.98]

Heart failure

2

30,392

0.94 [0.71 til 1.24]

Angina

1

24,309

0.91 [0.85 til 0.98]

ACE inhibitor vs. CCB (african american excluded)

Mortality (total)

2

16,080

1.03 [0.96 til 1.11]

AMI

2

16,080

0.96 [0.85 til 1.08]

Stroke

2

16,080

1.04 [0.92 til 1.19]

Heart failure

2

16,080

0.86 [0.80 til 0.93]

Angina

1

11,679

1.05 [0.95 til 1.15]

Diuretics vs. ACE inhibitor (african american excluded)

Mortality (total)

3

22,670

1.04 [0.96 til 1.12]

AMI

2

21,813

1.02 [0.93 til 1.12]

Stroke

3

22,670

0.98 [0.86 til 1.12]

Heart failure

2

22,670

0.97 [0.90 til 1.05]

Angina

1

15,730

0.95 [0.87 til 1.04]

  1. *In our analyses, we have used the meta-analysis results for diuretics for the effect of thiazides